

AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as follows:

Insert the following on page 4 at line 21:

Brief Description of the Drawings:

Fig. 1a-e)

Determination of the platelet aggregation induced by various agonists.

Fig. 2)

Determination of the von Willebrand ristocetin cofactor activity after a stirring time of 200 sec.

Fig. 3)

Determination of the von Willebrand ristocetin cofactor activity after a stirring time of 30 sec.

Fig. 4)

Determination of the von Willebrand ristocetin cofactor activity of standard human plasma dilutions after a stirring time of 30 sec.

Fig. 5)

Determination of the von Willebrand ristocetin cofactor activity after a stirring time of 5-60 sec.

Fig. 6)

Establishment of calibration plots with standard human plasma dilutions after a stirring time of 5-60 sec.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Fig. 7a)

Determination of the ADP concentration dependence of platelet aggregation with and without continuous stirring.

Fig. 7b)

Determination of the loss of activity through storage of platelet-rich plasma at room temperature by measuring the aggregation with ADP as agonist with and without continuous stirring.

Delete page 13.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com